GRIN3A

Glutamate receptor ionotropic, NMDA 3A · Q8TCU5 · GRIN3A on Sugi Atlas →

91,572 patent compounds predicted against GRIN3A, 51,439 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Ditolylguanidine (SCHEMBL80339)	1.00	14/20
SCHEMBL123451	0.55	14/20
SCHEMBL121942	1.00	11/20
Guanabenz (SCHEMBL15390)	0.65	11/20
Memantine (SCHEMBL2688)	1.00	9/20
Memantine (SCHEMBL2689)	1.00	9/20
Memantine (SCHEMBL3053)	0.95	9/20
Levorphanol (SCHEMBL24335)	1.00	8/20
Racemorphan (SCHEMBL46201)	1.00	8/20
Dextrorphan (SCHEMBL115577)	1.00	8/20
SCHEMBL103596	0.44	8/20
Dextromethorphan (SCHEMBL29949)	1.00	7/20
Levomethorphan (SCHEMBL29950)	1.00	7/20
SCHEMBL78658	1.00	7/20
Radiprodil (SCHEMBL99256)	1.00	7/20
Racemethorphan (SCHEMBL118520)	1.00	7/20
Radiprodil (SCHEMBL134435)	0.98	7/20
Radiprodil (SCHEMBL135546)	0.98	7/20
Dextromethorphan (SCHEMBL121924)	0.98	7/20
Dextrorphan (SCHEMBL122564)	0.98	7/20

Clinical trials — most relevant to GRIN3A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
PCA Ketamine-Morphine VS PCA Morphine as Post-Operative Analgesia in Colorectal Surgery.	PHASE4	COMPLETED
A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial	PHASE2/PHASE3	NOT_YET_RECRUITING
A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease	PHASE3	COMPLETED
TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders	PHASE3	RECRUITING
Independent Studies of Dextromethorphan and of Donepezil Hydrochloride for Rett Syndrome	PHASE3	UNKNOWN
Memantine for Refractory OCD Patients	PHASE3	UNKNOWN
Prehospital Early Administration of Ketamine for Status Epilepticus in Epileptic Kids (PEAK-SEEK)	PHASE2/PHASE3	RECRUITING
Effects of GABA-a-Agonists on Pain Mechanisms: An Experimental Study in Healthy Volunteers	PHASE3	COMPLETED
Safety and Efficacy Study of Topiramate to Aid in Smoking Cessation	PHASE3	COMPLETED
Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia	PHASE2	COMPLETED
Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder	PHASE2	COMPLETED
High Dose D-Serine as Adjuvant Treatment for Recent Onset Schizophrenia	PHASE2	UNKNOWN
Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders	PHASE2	COMPLETED
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression	PHASE1	RECRUITING
Antidepressant Effects of NR2B in Major Depression	PHASE1	COMPLETED
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response, Pilot Trial	PHASE1	COMPLETED
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response	PHASE1	RECRUITING
D-aspartate and Therapeutic Exercise	EARLY_PHASE1	UNKNOWN
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine	EARLY_PHASE1	COMPLETED
The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease	nan	COMPLETED
Tolerability and Efficacy of L-Serine in Patients With GRIN-related Encephalopathy	nan	UNKNOWN
An Assessment of Cognitive Function in Irritable Bowel Syndrome	nan	UNKNOWN
Acamprosate: Genes Associated With Response	nan	COMPLETED
Integrins and Protocadherins in Glutamatergic Circuits: Identification of Common Signaling Pathways and Molecular Targets in Anxiety and Major Depressive Disorders (GAPsy)	nan	UNKNOWN
PET Imaging of Brain mGluR1 Receptors Using [18F]FIMX	nan	COMPLETED
Mechanisms of Human Plasticity in the Human System	nan	COMPLETED
The Neuroprotective Effect of Dexmedetomidine Preserving Brain Functional Connectivity in Elderly Patients	nan	COMPLETED
Oral Ketamine as an Adjuvant to Opioids for Pain Treatment in Cancer Patients	nan	UNKNOWN
Metabotropic Receptors For Glutamate Type 3 In Parkinson's	nan	UNKNOWN
7 Tesla MRI Brain Imaging to Decipher Filgotinib's Mode of Analgesic Action in Rheumatoid Arthritis	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a GRIN3A binder may also engage these)

Protein	Name	Similarity
A2AIR5	—	1.000	A2AIR5 →
Q9R1M7	—	1.000	Q9R1M7 →
GRIN2C	Glutamate receptor ionotropic, NMDA 2C	0.977	landscape →
Q00961	—	0.974	Q00961 →
Q01098	—	0.973	Q01098 →
Q62645	—	0.953	Q62645 →
Q03391	—	0.953	Q03391 →
GRIN2D	Glutamate receptor ionotropic, NMDA 2D	0.948	landscape →
GRM8	Metabotropic glutamate receptor 8	0.946	landscape →
Q9H2Y9	—	0.946	Q9H2Y9 →
Q5RDQ8	—	0.946	Q5RDQ8 →
Q80ZF8	—	0.945	Q80ZF8 →
P24786	—	0.944	P24786 →
GRM4	Metabotropic glutamate receptor 4	0.944	landscape →
Q91YD4	—	0.943	Q91YD4 →
NTRK3	NT-3 growth factor receptor	0.942	landscape →
Q9QZC1	—	0.942	Q9QZC1 →
Q68EF4	—	0.942	Q68EF4 →
Q91987	—	0.942	Q91987 →
Q5IS37	—	0.941	Q5IS37 →
Q68ED2	—	0.941	Q68ED2 →
P47743	—	0.941	P47743 →
Q1ZZH0	—	0.941	Q1ZZH0 →
Q4R766	—	0.941	Q4R766 →
Q63604	—	0.941	Q63604 →
Q91044	—	0.941	Q91044 →
Q6AYT7	—	0.941	Q6AYT7 →
Q03351	—	0.941	Q03351 →
P70579	—	0.940	P70579 →
SCNN1A	Epithelial sodium channel subunit alpha	0.940	landscape →